Quadrivalent HPV for types 6, 11, 16 and 18

ApprovedCompleted
0 views this week 0 watching Active
Interest: 43/100
43
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
Phase 3
5
Approved
Indication / Disease

Cervical Cancer

Conditions

Cervical Cancer, Hpv, Warts

Trial Timeline

May 1, 2010 → Dec 14, 2012

About Quadrivalent HPV for types 6, 11, 16 and 18

Quadrivalent HPV for types 6, 11, 16 and 18 is a approved stage product being developed by Merck for Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01101750. Target conditions include Cervical Cancer, Hpv, Warts.

What happened to similar drugs?

7 of 20 similar drugs in Cervical Cancer were approved

Approved (7) Terminated (0) Active (13)
V501MerckApproved
Gardasil 9MerckApproved
TIVDAKPfizerApproved
PregabalinPfizerApproved
Botox injectionBrain BiotechApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01101750ApprovedCompleted

Competing Products

20 competing products in Cervical Cancer

See all competitors
ProductCompanyStageHype Score
PRGN-2009 plus Pembrolizumab + Pembrolizumab alonePrecigenPhase 2
36
ABP-450AEON BiopharmaPhase 2
25
ABP-450 + PlaceboAEON BiopharmaPhase 2
25
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
exatecan mesylateDaiichi SankyoPhase 2
35
Trastuzumab deruxtecanDaiichi SankyoPhase 2
42
Sacituzumab tirumotecan plus IparomlimabSun PharmaceuticalPhase 2
42
Amolimogene + AmolimogeneEisaiPhase 2/3
38
BOTULINUM TOXIN TYPE BEisaiPhase 2
35
Gemzar (gemcitabine)Eli LillyPhase 3
36
PemetrexedEli LillyPhase 2
35
SHR-A1811 InjectionJiangsu Hengrui MedicinePhase 2
42
camrelizumab; famitinib malate + platinum-based chemotherapyJiangsu Hengrui MedicinePhase 3
44
SHR-1210 + SHR-1020 + Physician's choice chemotherapyJiangsu Hengrui MedicinePhase 2
35
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
31
Camrelizumab + Cisplatin or CarboplatinJiangsu Hengrui MedicinePhase 2
31
Volrustomig + Cisplatin + Carboplatin + PaclitaxelAstraZenecaPhase 2
42
VolrustomigAstraZenecaPhase 3
47
Durvalumab + Cisplatin + CarboplatinAstraZenecaPhase 3
40
VolrustomigAstraZenecaPhase 2
39